ONCOLOGY Nurse Edition April 2009, Vol 23 No 4

A Sneak Peek at 2025 ASCO From the GU Perspective

Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy in this squamous cell carcinoma of the anal canal population.

Russ Conroy

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy

May 14th 2025

FDA Approves At-Home Cervical Cancer Screening Kit

Related Content

Ariana Pelosci

A Sneak Peek at 2025 ASCO From the GU Perspective

Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Russ Conroy

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD